For over three decades, the primary method of therapy used by almost all physicians for the management of acute deep-vein thrombosis and pulmonary embolism has been anticoagulation. This form of therapy has become so ingrained in medical practice that physicians, while still concerned over the bleeding risk associated with the use of anticoagulants, nevertheless seem secure in the belief that they are providing optimal, if not ideal, therapy for these disorders. With the advent of thrombolytic therapy, this is no longer true for a large number of cases. Anticoagulation for the management of acute deep-vein thrombosis and pulmonary embolism, while usually effective in preventing or slowing further thrombus formation in veins and significantly diminishing the likelihood of subsequent or recurrent embolisation, does not: * eliminate the source of subsequent embolisation in the deep veins during the acute attack; * alleviate the haemodynamic disturbances associated with the thrombosis or embolism; * prevent subsequent valvular damage to the deep veins and the development of persistent venous hypertension and associated symptoms in the lower extremities which may predispose to recurrent deep-vein thrombosis and pulmonary embolism; * prevent permanent impairment to the pulmonary vascular bed and, in patients with more extensive involvement, persistence of pulmonary hypertension.
The reason that patients with acute deep-vein thrombosis and pulmonary embolism treated with anticoagulation alone are subject to these complications is that such therapy has no acute effect on previously formed thrombi or emboli. Its role is primarily that of secondary intervention-that is, prophylaxis against further thrombus growth, recurrence, and embolisation. The natural history of underlying thrombi and emboli treated with anticoagulation alone is mainly one of organisation and recanalisation.
Uses of thrombolytic treatment
From these considerations it is apparent that ideal therapy for acute deep-vein thrombosis and pulmonary embolism requires either the surgical removal or lysis of the thrombus or embolus so as to restore to normal the haemodynamics and integrity of the vasculature and the subsequent prevention of recurrence of thrombosis. On the basis of present experience a surgical approach is usually unsuccessful except under very limited conditions.
However, the lysis of thrombi and emboli can be successfully accomplished in a large number of patients through the proper use of thrombolytic agents. When used in conjunction with anticoagulants thrombolytic therapy can achieve the objectives of ideal management as follows: * lyse thrombi and emboli and restore the circulation to normal; * normalise the haemodynamic disturbances and reduce morbidity; * prevent venous valvular damage and subsequent venous hypertension in the lower extremities; and * prevent permanent damage to the pulmonary vascular bed and reduce the likelihood of persisting pulmonary hypertension. Additional undersirable effects that have been observed in association with thrombolytic therapy include fever and allergic reactions. These occur at a low frequency, are mild, and seldom result in any physiological injury or the need to discontinue therapy. Anaphylactoid reactions observed with older preparations no longer in use are very rarely observed with the presently employed agents. When such reactions have been observed they uniformly respond to conventional therapy. (4) Assuming there are proved benefits and a favourable risk: benefit ratio, why are these drugs not being used more frequently?
The panel agreed that while some rationales for deciding against the use of thrombolytic agents were reasonable, such as an inadequate clinical indication or the risk of serious haemorrhage, others were unreasonable. These unreasonable rationales are partly the result of reports of the large multi-centre urokinase and streptokinase pulmonary embolism trials with their complex biochemical and physiological studies that required many invasive procedures, and also of the early experience using thrombolytic agents that were less pure than current products and which caused more frequent pyrogenic and allergenic side effects. The unreasonable rationales include the following:
Fear of bleeding-The urokinase and streptokinase pulmonary embolism trials showed a high incidence of bleeding both with thrombolytic agents and with heparin. However, the incidence of significant bleeding was only 9 % for urokinase-streptokinase and 4% for heparin. The incidence of major bleeding complications with lytic agents during recent clinical experience-that is, since the drugs have been available for general use by doctors-has been about 5 %. This is based on the patient treatment forms returned to pharmaceutical manufacturers during the continuing surveillance period requested by the Bureau of Biologics, Food and Drug Administration.
Need for additional invasive procedures-The diagnostic procedures required for thrombolytic therapy are no different from those required for heparin. Objective diagnostic procedures are required for both. Confusion regarding dose regulation-There are many directives suggested by the package insert and the general literature that are complex and confusing. For instance, increasing the dose of streptokinase in order to decrease the proteolytic effect is scientifically accurate but is unnecessary with a fixed-dose schedule. Additionally, the streptokinase resistance test is unnecessary, given the 90 00 expectation of inducing a lytic state by the standard loading dose followed by a fixed dose schedule. Altering or eliminating such directives in the package insert would simplify treatment.
Limited availability of laboratory assays-Although research studies used many highly sophisticated assays for following thrombolytic treatment, any one of a number of assays can now be used to reflect the circulating "lytic state," the simplest of which is the thrombin time. Whatever the choice of the physician (plasminogen, lysis time, prothrombin time, activated partial thromboplastin time, fibrinfibrinogen degradation products, fibrinogen, etc) at least one of these assays will be available for use by the practitioner in any hospital laboratory.
"Evaluate response to heparin first"-Any delay in instituting lytic therapy in order to determine whether heparin achieves an initial good response will decrease the potential for optimal response. Therefore, therapy with urokinase or streptokinase should not be deferred after the diagnosis has been established for any reason other than the presence of a serious contraindication to use. Decision by committee-The decision to treat need not be made by a committee; such a decision may be made by an informed clinician who is prepared to manage such a patient with a lytic agent.
(5) What are the guidelines for patient management and monitoring?
* The diagnosis should be established with objective techniques. If pulmonary angiography is performed the upper extremity should be used. * Before thrombolytic infusion, the following laboratory tests are indicated: a thrombin time (TT), activated partial thromboplastin time (APTT), prothrombin time (PT), packed cell volume, and platelet count. If heparin has been given it should be discontinued and the TT or APTT should be less than twice the normal control value before thrombolytic therapy is started. * Begin the thrombolytic infusion. During therapy no invasive procedures should be performed with the exception of careful venepuncture with a 22-or 23-guage needle for therapeutic monitoring. If essential, arterial blood gas studies can be performed (in the arm), but digital compression of the puncture site for at least 30 minutes is mandatory. The patient should be at strict bed rest and pressure dressings applied to previously invaded sites. No new medication should be added to the therapeutic regimen unless absolutely essential. No medication should be added to the bottle containing the thrombolytic agent. * Vital signs-pulse, temperature, respiratory rate, and blood pressure-should be measured every four hours during infusion. 
